FDA to ramp up cell and gene therapy activity as tidal wave of new products approaches
In a statement, Commissioner Scott Gottlieb said the agency anticipates more than 200 cell and gene therapy INDs per year by 2020, and 10-20 approvals annually by 2025.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
